Form D · Pharmaceuticals

WEIKANG BIO-TECHNOLOGY GROUP CO., INC.

Harin, Heilongjiang Province, F4 · CIK 0001484042

Offering snapshot reported Feb 7, 2011 · SEC filing

Reported sold
$5M
Offering amount: $5M
Investors reported
38
Form D · investor count
Minimum accepted
$1M
Reported outside-investor minimum
First sale
Dec 2, 2010
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$2.5M$5MDec 15, 2010: $2,499,994.00Dec 15, 2010Feb 7, 2011: $4,999,974.00Feb 7, 2011

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$2,499,994 → $4,999,974
  • Reported investors21 → 38

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 7, 2011Amendment$4,999,974$2,499,980vs Dec 15, 201038SEC filing
Dec 15, 2010Initial$2,499,994No comparison21SEC filing
Feb 18, 2010Initial$2,500,000No comparison3SEC filing

Offering details

Securities
Other
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$555K (estimated)
Finders' fees
$0
Form D file number
021-151927
Each unit consists of four shares of common stock; a three-year warrant to purchase one share of common stock at an exercise price of $ 3.60 per share, and a three-year warrant to purchase one share of common stock at an exercise price of $4.80 per share.
Aggregate of approximately $554,559.96 as commission and compensation for advisory related services.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Hunter Wise Financial Group, LLCNoneHunter Wise Securities, LLC · CRD 104193
National Securities Corporation7569
Pacific Summit CapitalNonePacific Summit Securities · CRD 30993
Anderson & Strudwick, Inc.48

Source: Form D, filed Feb 7, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Yan Huang Director
Yilun Jin Director
Yuanyuan Jing Director
Yanhua Liu Director, Executive
Baolin Sun Executive
Weili Wang Director
Wei Wang Director
Guangxin Wang Director
Yin Wang Director, Executive
Allen Zhang Director
Yvonne Zhang Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
No. 365 Chengde Street Daowai District
Harin, Heilongjiang Province, F4, 150020